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To grow beyond minimal size, tumors must in-
duce the formation of new blood vessels (1, 2). 
They do so by secreting angiogenic factors, in-
cluding basic fi  broblast growth factor (bFGF), 
platelet-derived growth factor B, and members 
of the vascular permeability factor (VPF)/vas-
cular endothelial growth factor (VEGF) family 
(3). Among these, VPF/VEGF (VEGF-A) is 
thought to be the most important for several 
reasons. It is expressed abundantly by most hu-
man and animal tumors and is able by itself to 
induce typical tumor blood vessels. In addition, 
when neutralized, the growth of VEGF-A–ex-
pressing tumors is strikingly inhibited (3, 4). 
VEGF-A is a multifunctional cytokine that acts 
through receptors that are expressed on vascu-
lar endothelium as well as on some other cell 
types. After interaction with VEGF-A, endo-
thelial cells undergo extensive reprogramming 
of protease, integrin, and glucose transporter 
expression; are stimulated to migrate and di-
vide; and are protected from apoptosis and 
  senescence (4, 5). In addition, VEGF-A and 
other VPF/VEGF family members are the 
only angiogenic cytokines identifi  ed thus far 
that render microvessels hyperpermeable to 
circulating macromolecules, a characteristic 
property of tumor and other angiogenic blood 
vessels (3).
Although extensive eff  orts have been made 
to delineate the mechanisms by which VEGF 
induces angiogenesis, little is known about the 
transcriptional events that regulate this impor-
tant process. We therefore set out to identify 
endothelial cell immediate-early response genes 
whose expression was induced by VEGF-A 
with the thought that such genes might play key 
downstream roles in regulating angiogenesis. 
We performed DNA microarrays on cultured 
human umbilical vein endothelial cells (HU-
VECs) stimulated with VEGF-A165 and found 
that several genes were up-regulated. Among 
the most highly induced was TR3 (mouse ho-
mologue Nur77), an immediate-early response 
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Vascular endothelial growth factor (VEGF)-A has essential roles in vasculogenesis and 
angiogenesis, but the downstream steps and mechanisms by which human VEGF-A acts are 
incompletely understood. We report here that human VEGF-A exerts much of its angio-
genic activity by up-regulating the expression of TR3 (mouse homologue Nur77), an imme-
diate-early response gene and orphan nuclear receptor transcription factor previously 
implicated in tumor cell, lymphocyte, and neuronal growth and apoptosis. Overexpression 
of TR3 in human umbilical vein endothelial cells (HUVECs) resulted in VEGF-A–independent 
proliferation, survival, and induction of several cell cycle genes, whereas expression of 
antisense TR3 abrogated the response to VEGF-A in these assays and also inhibited tube 
formation. Nur77 was highly expressed in several types of VEGF-A–dependent pathological 
angiogenesis in vivo. Also, using a novel endothelial cell-selective retroviral targeting 
system, overexpression of Nur77 DNA potently induced angiogenesis in the absence of 
exogenous VEGF-A, whereas Nur77 antisense strongly inhibited VEGF-A–induced angio-
genesis. B16F1 melanoma growth and angiogenesis were greatly inhibited in Nur77−/− 
mice. Mechanistic studies with TR3/Nur77 mutants revealed that TR3/Nur77 exerted most 
of its effects on cultured HUVECs and its pro-angiogenic effects in vivo, through its trans-
activation and DNA binding domains (i.e., through transcriptional activity).
CORRESPONDENCE
H. Zeng:
hzeng@bidmc.harvard.edu
Abbreviations used: bFGF, basic 
fi  broblast growth factor; 
HUVEC, human umbilical 
vein endothelial cell; LBD, 
ligand binding domain; MOT, 
mouse ovarian tumor; VEGF, 
vascular endothelial growth factor; 
VPF, vascular permeability 
factor.720  ROLE OF TR3/NUR77 IN VEGF-INDUCED ANGIOGENESIS | Zeng et al.
gene and member of the class IV subfamily of the orphan nu-
clear receptor superfamily of transcription factors (6). TR3/
Nur77 was known as an important regulator of cell growth 
and apoptosis in tumor cells, lymphocytes, and neurons (7, 8), 
but a role in angiogenesis had not been anticipated. We here 
report that TR3/Nur77 is both necessary and suffi   cient for 
VEGF-A–induced proliferation and survival of cultured en-
dothelial cells and for angiogenesis in vivo.
RESULTS
Expression and function of TR3 in vitro
Up-regulation of TR3 in HUVECs. Serum-starved HU-
VECs were stimulated with 10 ng/ml VEGF-A165 for 1 h, 
and RNA was isolated and its expression assessed on Aff  yme-
trix DNA microarray chips. In agreement with a recent re-
port (9), VEGF-A165 highly up-regulated TR3 and we 
confi  rmed this fi  nding by quantitative real-time RT-PCR 
and immunoblotting (Fig. 1, A and B). [ID]FIG1[/ID] TR3 was also in-
duced, although to a slightly lesser extent, by another VEGF-
A isoform, VEGF-A120, but not by several other angiogenic 
growth factors including bFGF, platelet-derived growth fac-
tor, and placenta growth factor, another member of the VPF/
VEGF family (Fig. 1 C).
Cloning and expression of TR3 sense and antisense 
cDNAs and mutants. To elucidate TR3/Nur77’s role 
in angiogenesis-related events, we constructed TR3-sense 
(TR3-S) and TR3-antisense (TR3-AS) DNAs. In addition, 
TR3/Nur77, like other members of the orphan nuclear re-
ceptor superfamily, has three functionally distinct domains: 
transactivation, DNA binding, and ligand binding (10, 11). 
Therefore, we engineered mutant forms of TR3/Nur77 that 
lacked each of these domains, as previously described (Fig. 2 
A;  <CIT>reference 11 </CIT>).[ID]FIG2[/ID] Each of these constructs was fused with the 
Flag tag and then transduced into HUVECs using an effi   cient 
retroviral system that yielded almost 100% infection (12). 
HUVECs retrovirally transfected with TR3-S DNA exhib-
ited a three- to fourfold increase in TR3 protein expression 
as compared with untransfected cells or HUVECs transduced 
Figure 1.  VEGF-A induces TR3 expression in cultured HUVECs. 
(A) Quantitative real-time RT-PCR to demonstrate TR3 and control GAPDH 
mRNA expression after stimulation with 10 ng/ml VEGF-A165 at times 
indicated. (B) Immunoblot of TR3 protein expression in VEGF-A165–
  stimulated HUVECs (top). Bottom shows MAPK protein loading control. 
(C) TR3 mRNA expression in HUVECs stimulated with 10 ng/ml VEGF-A165, 
VEGF-A120, placenta growth factor, platelet-derived growth factor (PDGF), 
or with 25 ng/ml bFGF over time as determined by quantitative real-time 
RT-PCR (n = 2).
Figure 2.  TR3 and Nur77 mutants. Expression of TR3/Nur77 sense, 
antisense, and mutant proteins in transfected HUVECs. (A) Schematic 
structure of TR3 and Nur77 genes and mutants constructed to lack TAD, 
DBD, or LBD domains. (B) Expression of TR3 protein in control HUVECs 
and in HUVECs transfected with TR3-S, TR3-AS, or LacZ cDNAs. TR3-S–
transfected HUVECs expressed three- to fourfold more TR3 protein than 
untransfected or LacZ-transfected cells. Endogenous TR3 protein expres-
sion was strongly inhibited in cells transfected with TR3-AS. Bottom 
shows MAPK protein loading control. (C) Expression of Flag-TR3-∆TAD, 
Flag-TR3-∆DBD, and Flag-TR3-∆LBD in HUVECs. (D) Subcellular localiza-
tion of GFP-fused TR3 mutants in HUVECs.JEM VOL. 203, March 20, 2006  721
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with LacZ. On the other hand, HUVECs transfected with 
TR3-AS expressed greatly diminished amounts of TR3 pro-
tein (Fig. 2 B). All three mutant forms of TR3 were expressed 
and to similar extents (Fig. 2 C). GFP fusion proteins were 
prepared with each mutant and their subcellular distribu-
tion followed after introduction into HUVECs. GFP-TR3-
∆DBD protein was localized to the HUVEC cytosol, whereas 
GFP-TR3-∆TAD and GFP-TR3-∆LBD, like GFP-TR3-S, 
were confi  ned to the nucleus (Fig. 2 D). We then tested each 
of these transfected cells using in vitro angiogenesis assays that 
measured cell proliferation, survival, and tube formation.
Endothelial cell proliferation assay. Serum-starved HU-
VECs transduced with LacZ (control), TR3-S, or TR3-AS 
DNAs were cultured for 24 h with or without VEGF-A165, 
and cell proliferation was assessed by 4-h [3H]thymidine in-
corporation (12). As shown in Fig. 3 A, HUVECs transduced 
with TR3-S strongly incorporated [3H]thymidine (lane 3 vs. 
lane 1; P < 0.001) in the absence of added VEGF-A165 and in 
amounts equivalent to those induced by VEGF-A165 in LacZ-
transduced cells (lane 3 vs. lane 2; P > 0.5). [ID]FIG3[/ID] Incorporation 
was not enhanced further when VEGF-A165 was added (Fig. 3 
A, lane 4 vs. lane 3; P>0.5). HUVECs transduced with TR3-
AS incorporated [3H]thymidine at baseline levels (Fig. 3 A, 
lane 5 vs. lane 1), but incorporation was not increased by the 
addition of VEGF-A165 (lane 6 vs. lane 2; P < 0.001).
We next investigated [3H]thymidine incorporation in 
HUVECs transduced with mutant TR3s that lacked each of 
its three domains. As shown in Fig. 3 A, HUVECs transfected 
with TR3 mutants lacking the transactivation (∆TAD) or 
DNA binding (∆DBD) domains incorporated [3H]thymidine 
at baseline levels but were not stimulated to increased incorpo-
ration by VEGF-A165. These data suggest that TR3 transcrip-
tional activity is required for VEGF-A165–induced HUVEC 
proliferation. However, HUVECs transfected with the TR3 
mutant that lacked the ligand binding domain (∆LBD) be-
haved like HUVECs transfected with full-length TR3-S, ex-
hibiting greatly increased [3H]thymidine incorporation in the 
absence of added VEGF-A165. In addition, incorporation was 
not further enhanced by the addition of VEGF-A165. Thus, 
the LBD is apparently not required for the enhanced prolif-
erative response observed after TR3 transfection.
Endothelial cell survival assay. HUVECs undergo apop-
tosis when cultured in the absence of serum and VEGF-A165 is 
known to protect endothelial cells from apoptosis (13). After 
3 d of culture in the absence of serum and VEGF-A165, >70% 
of LacZ-transfected HUVECs underwent apoptosis (Fig. 3 B, 
lane 1). As expected, the addition of VEGF-A165 protected 
such HUVECs, reducing apoptosis by approximately one 
half (Fig. 3 B, lane 2 vs. lane 1; P < 0.001). HUVECs trans-
fected with TR3-S DNA, without added VEGF-A165, also 
showed reduced apoptosis, similar to that of LacZ-transfected 
HUVECs treated with VEGF-A165 (Fig. 3 B, lane 3 vs. lane 
2; P > 0.05); the addition of VEGF-A165 reduced apoptosis 
slightly further (lane 4). However, in HUVECs transduced 
with TR3-AS DNA, nearly 80% of cells were apoptotic and 
the addition of VEGF-A165 did not signifi  cantly improve cell 
survival (Fig. 3 B, lanes 5 and 6; P > 0.05). HUVECs trans-
duced with any of the mutant TR3 DNAs underwent nearly 
100% apoptosis and could not be rescued by the addition of 
VEGF-A165 (Fig. 3 B, lanes 7–12; P > 0.05). Thus, overex-
pression of full-length TR3, but not mutants lacking any of 
its domains, protects HUVECs from apoptosis in the absence 
of added VEGF-A165. In addition, VEGF-A165 was not able 
to protect from apoptosis HUVECs that had been transfected 
with any of the domain-lacking mutants.
Tube formation assay. HUVECs or HUVECs transfected 
with LacZ form characteristic tubal networks when cultured 
on Matrigel in growth medium for 18 h (Fig. 3 C, a). TR3-
S–transfected HUVECs formed similar networks (Fig. 3 C, b). 
Figure 3.  Assays measuring functional capabilities of cultured 
HUVECs transfected with TR3-S, TR3-AS, and TR3 mutant cDNAs, 
with or without VEGF-A165 stimulation. (A) [3H]thymidine incorpora-
tion ( <CIT>reference 12 </CIT>; n = 4). (B) Cell survival assay (n = 4). (C) Tube forma-
tion on Matrigel.722  ROLE OF TR3/NUR77 IN VEGF-INDUCED ANGIOGENESIS | Zeng et al.
However, HUVECs transfected with TR3-AS or with TR3-
∆TAD formed greatly reduced numbers of tubes (Fig. 3 C, 
c and d). TR3-∆LBD–transfected HUVECs approximated the 
normal network pattern but formed a somewhat looser mesh-
work (Fig. 3 C, f). Finally, cells transfected with TR3-∆DBD 
remained as a confl  uent monolayer and exhibited no evi-
dence of network formation (Fig. 3 C, e). These data indicate 
that TR3 has an important role in HUVEC tube formation 
and that the ∆TAD and especially the ∆DBD domain are 
particularly important in this process.
TR3 regulates expression of cell cycle–related genes. 
VEGF-A165 is known to induce the expression of several cell 
cycle–related genes in HUVECs (14). Therefore, we investi-
gated whether TR3 had a similar eff   ect. We found that 
VEGF-A165 induced the expression of cyclins A and D1, 
PCNA, and E2F in HUVECs transduced with LacZ (Fig. 4, 
panel 1) and also in untransfected HUVECs (not depicted). [ID]FIG4[/ID] 
In HUVECs transduced with TR3-AS, baseline expression 
of these genes was reduced or similar to that of LacZ-trans-
duced cells, and expression was either not increased or in-
creased to a lesser extent after the addition of VEGF-A165 
(Fig. 4, panel 2). In addition, expression of all four of these 
genes was increased in TR3-S–transduced cells in the ab-
sence of VEGF-A165 (Fig. 4, panel 3). In TR3-∆LBD–trans-
fected cells, expression of these genes was roughly similar to 
that of LacZ-transduced cells and was comparably stimulated 
upon exposure to VEGF-A165 (Fig. 4, panel 4). However, 
HUVECs transduced with TR3-∆TAD or TR3-∆DBD did 
not express detectable amounts of any of these genes, with or 
without the addition of VEGF-A165 (Fig. 4, panels 5 and 6). 
Consistent with these data, HUVECs transfected with TR3-
AS, TR3-∆TAD, or TR3-∆DBD grew much more slowly 
in culture than control or Lac-Z–transfected cells.
Expression and function of Nur77 (the mouse TR3 
homologue) in vivo
Expression of Nur77 in angiogenesis assays in vivo. 
Our experiments with cultured endothelium suggested that 
TR3 could have an important role in regulating angiogenesis. 
To test this possibility, we investigated whether Nur77, the 
mouse homologue of TR3, was induced in the course of 
VEGF-A–mediated angiogenesis in vivo. We fi  rst injected an 
adenoviral vector expressing VEGF-A164 (the murine equiv-
alent of human VEGF-A165) into nude mouse ear skin to 
generate a strong local angiogenic response (Fig. 5 A)  <CIT>(15</CIT>).[ID]FIG5[ /ID] 
We found that Nur77 mRNA and protein expression were 
strongly up-regulated in a time-dependent fashion (Fig. 5, B 
and C) that correlated temporally with the early angiogenic 
response, which is characterized by the formation of enlarged, 
pericyte-poor “mother” vessels (15). Healing skin wounds 
and TA3/St and mouse ovarian tumor (MOT) ascites tumors 
induced a similar, VEGF-A–driven angiogenic response (16, 
17), and we found that Nur77 expression was up-regulated in 
all three of these examples (Fig. 5 D). However, Nur77 was 
not detected in immunoblots of TA3/St or MOT tumor cell 
extracts (not depicted). Collectively, these data demonstrate 
that Nur77 is strongly up-regulated in several diff  erent exam-
ples of VEGF-A–induced angiogenesis.
Nur77 regulates angiogenesis in Matrigel assays in 
vivo. To elucidate Nur77’s mechanism of action, we made 
use of a recent modifi  cation of the Matrigel assay to intro-
duce genes of interest into vascular endothelium in vivo (18). 
SK-MEL-2 melanoma cells that had been transfected to 
overexpress VEGF-A165 (SK-MEL/VEGF cells) (18 </CIT>), and 
PT67 cells packaging retroviruses that expressed LacZ, 
Nur77-sense (S), or Nur77-antisense (AS), were incorpo-
rated into Matrigel plugs that were injected into the s.c. space 
of nude mice. The VEGF-A165 secreted by SK-MEL/VEGF 
cells induces nearby vascular endothelial cells to divide and 
therefore to become susceptible to infection with retroviruses 
secreted by PT67 packaging cells (18).
Initial experiments confi  rmed that Nur77-S and Nur77-
AS RNAs were expressed by cells in Matrigels (Fig. 6 A, pan-
els A–D). [ID]FIG6[/ID] We then evaluated the angiogenic response that 
developed after implantation of Matrigel plugs containing 
various cell mixtures on days 1 (not depicted) and 3 (Fig. 7 A). [ID]FIG7[ /ID] 
Angiogenesis was assessed by macroscopy (Fig. 7 A, top pan-
els) and by histology and immunohistochemistry for the en-
dothelial cell marker CD31 (bottom panels). Plugs containing 
only PT67 cells that packaged LacZ-expressing retroviruses 
(PT67/LacZ cells) did not induce considerable angiogenesis. 
However, strong angiogenesis was induced in plugs contain-
ing SK-MEL/VEGF cells, whether alone or combined with 
PT67/LacZ cells. The angiogenic response was characterized 
Figure 4.  TR3 regulation of cell cycle gene expression in HUVECs. 
Immunoblots of cell extracts from HUVECs transfected with LacZ, TR3-S, 
TR3-AS, and TR3 mutant DNAs, with or without VEGF-A165 stimulation for 
indicated times. Actin expression serves as a protein loading control.JEM VOL. 203, March 20, 2006  723
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by the formation of mother vessels, enlarged, thin-walled, 
pericyte-poor vessels typical of early VEGF-A–induced an-
giogenesis (15). In situ hybridization confi  rmed that Nur77 
was induced in gels containing SK-MEL/VEGF (Fig. 6 B). 
When PT67/Nur77-AS cells were included in the Matrigel, 
the angiogenic response induced by SKMEL/VEGF cells was 
strikingly inhibited (Fig. 7 A). The eff  ect of Nur77-AS DNA 
was not attributable to inhibition of VEGF-A165 expression by 
tumor cells (Fig. 6 A, panels E and F). Furthermore, overex-
pression of TR3/Nur77-AS DNA in either SKMEL/VEGF 
or PT67 cells did not aff   ect proliferation as measured by 
[3H]thymidine incorporation (not depicted).
To further characterize the role of Nur77 in angiogenesis, 
we incorporated PT67/Nur77-S packaging cells into the 
Matrigel plugs, alone or along with SK-MEL/VEGF cells. 
Strong angiogenesis with mother vessel formation developed 
when PT67/Nur77-S cells were included along with SK-
MEL/VEGF cells (Fig. 7 A). Of particular interest, PT67/
Nur77-S cells induced signifi  cant angiogenesis with the for-
mation of mother vessels even in the absence of SK-MEL/
VEGF cells (Fig. 7 A), likely because Matrigel implants, as a 
foreign matrix, induced suffi   cient endothelial cell prolifera-
tion to allow some retroviral uptake. Collectively, these data 
indicate that Nur77 is able to induce typical angiogenesis in 
vivo in the absence of exogenous VEGF-A165.
Quantitation of angiogenesis induced by Nur77. To 
quantitate the angiogenic response, we measured the intravas-
cular volume of plasma contained within Matrigel plug-associ-
ated blood vessels. Evan’s blue dye was injected i.v. into mice 
1 and 3 d after implanting Matrigel plugs containing various 
cell mixtures. This dye binds to plasma proteins and therefore 
the amount of plasma within the Matrigel-associated vascu-
lature can be calculated from simultaneous measurements of 
dye concentration in peripheral blood plasma. Matrigel plugs 
were harvested 5 min after i.v. dye injection, when blood 
vessels were fi  lled with dye–plasma protein complexes but 
before there was time for signifi  cant extravasation.
Figure 5.  Increased expression of Nur77 in VEGF-A–induced an-
giogenesis. (A) Angiogenic response in nude mouse ears 5 d after intra-
dermal injection of Ad-VEGF-A164 (left ear). Ad-LacZ was injected in right 
ear as a negative control ( <CIT>reference 15 </CIT>). (B) Fold activation of Nur77 mRNA 
over time in mouse ears after intradermal injection of Ad-VEGF-A164 or 
Ad-LacZ as determined by quantitative real-time RT-PCR. (C) Immunoblots 
of Nur77 protein expression in uninjected mouse ears or in ears injected 
with Ad-LacZ or Ad-VEGF-A164 (top). Bottom shows MAPK protein loading 
control. (D) Immunoblots of Nur77 protein expression (top) in healing skin 
punch biopsy wounds and in mesenteries of nude mice bearing TA3/St and 
MOT ascites tumors. Bottom shows MAPK protein loading controls.
Figure 6.  Nur77 and VEGF-A expression in Matrigel assays. (A) In situ 
hybridization performed on Matrigels containing SK-MEL/VEGF cells and 
PT67 cells packaging either Nur77-S (left) or Nur77-AS–expressing retrovirus 
(right) cDNAs. Probes were Nur77-AS (A and C), Nur77-S (B and D), and 
VEGF-A165-AS (E and F). (B) In situ hybridization demonstrating Nur77 ex-
pression in newly formed blood vessels in Matrigels containing SK-MEL/
VEGF cells hybridized with Nur77-AS (A) or Nur77-S (B) probes. v, vessel.724  ROLE OF TR3/NUR77 IN VEGF-INDUCED ANGIOGENESIS | Zeng et al.
Intravascular dye accumulation in Matrigel plugs contain-
ing VEGF-A165–expressing SKMEL/VEGF cells (alone or 
with PT67/LacZ cells) increased more than twofold above 
baseline levels at 3 d in Matrigels lacking SKMEL/VEGF 
cells (Fig. 7 B, lanes 4 and 6 vs. lane 2; P < 0.001); the in-
crease at 1 d was smaller and not statistically signifi  cant (lanes 
3 and 5 vs. lane 1; P > 0.05). Inclusion of PT67 cells packag-
ing Nur77-AS DNA completely blocked the response of SK-
MEL/VEGF cells on day 3 (Fig. 7 B, lane 8 vs. lanes 4 and 6; 
P < 0.001). Dye accumulation in Matrigel plugs increased 
still further to more than threefold on day 3 when SKMEL/
VEGF cells were included along with PT67/Nur77-S cells 
(Fig. 7 B, lane 10 vs. lanes 4 and 6; P < 0.01). The increment 
in dye accumulation also achieved statistical signifi  cance on 
1 d (Fig. 7 B, lane 9 vs. lanes 1, 3, and 5; P < 0.001). However,
when PT67/Nur77-S cells were incorporated in Matrigel 
plugs in the absence of SKMEL/VEGF cells, dye accumula-
tion increased signifi  cantly by approximately twofold on day 
1 (Fig. 7 B, lane 11 vs. lanes 1, 3, and 5; P < 0.001). Dye ac-
cumulation in these plugs increased further at 3 d, similar to 
that of 3 d plugs containing SKMEL/VEGF cells, alone or 
with PT67/LacZ cells (Fig. 7 B, lane 12 vs. lanes 4 and 6; P > 
0.05). These data indicate that inclusion of cells packaging 
Nur77-S not only induces angiogenesis but does so more 
rapidly than that induced by SKMEL/VEGF cells, consistent 
with the activity of Nur77 being downstream that of VEGF-
A. The quantitative measurements of vascular plasma vol-
umes presented in Fig. 7 B therefore confi  rm the qualitative 
measures of angiogenesis presented in Fig. 7 A.
Inhibition of tumor growth in Nur77-null mice. To 
determine whether TR3/Nur77 is required for tumor-
  induced angiogenesis, we studied the growth of B16F1 
melanoma in Nur77−/− mice. 5 × 105 tumor cells were 
injected s.c. in wild-type and Nur77−/− mice, and tumor 
growth was monitored daily. As shown in Fig. 8, A and B, 
a, tumors grew to large size in wild-type mice but growth 
in null mice was greatly inhibited (P < 0.001).[ID]FIG8[/ID] Inhibition 
of tumor growth in Nur77−/− mice was associated with re-
duced angiogenesis and particularly with a reduction in the 
generation of large mother vessels (Fig. 8 B, b–e). B16F1 
melanoma cells are syngeneic in C57Bl6 mice and therefore 
do not generate a cellular immune response. Nonetheless, 
because TR3/Nur77 has been implicated in apoptosis of T 
lymphocytes (8), we made a careful search for infl  ammatory 
cells. Small numbers of macrophages were found infi  ltrating 
tumors in both wild-type and Nur77−/− mice, but lympho-
cytes were not found. Therefore, it is unlikely that the inhi-
bition of tumor growth in Nur77−/− mice is attributable to 
a T lymphocyte defect.
Mechanisms by which Nur77 induces angiogenesis in vivo
Nur77 acts independently of VEGFR-2/KDR. The data 
presented above provided evidence that the angiogenic 
Figure 7.  Angiogenic response induced by Nur77-S or Nur77-AS 
in Matrigel assays in vivo. (A) Macroscopic (top) and CD-31–stained 
microscopic (bottom) images of the angiogenic response induced 3 d 
after implantation of Matrigels with indicated contents of VEGF-A165–
secreting SKMEL/VEGF cells and PT67 cells packaging LacZ, Nur77-S, or 
Nur77-AS. (B) Quantitative measurement of intravascular plasma volumes 
(μl/g) in Matrigels containing indicated cell mixtures at 1 and 3 d after 
implantation as determined by accumulation of Evan’s blue dye adminis-
tered i.v. 5 min before killing.JEM VOL. 203, March 20, 2006  725
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  response induced by Nur77 developed earlier than that in-
duced by VEGF-A165, suggesting that Nur77 functioned 
downstream of VEGF-A165. Nonetheless, it was possible 
that Nur77 acted in part by inducing VEGF-A expression. 
To test that possibility, we made use of SU1498, a VEGFR-2/
KDR kinase inhibitor that is known to inhibit VEGF-
A165–induced angiogenesis (19). In Matrigel assays, SU1498 
strongly inhibited the angiogenic response induced by SK-
MEL/VEGF cells (i.e., by VEGF-A165) but had no inhibi-
tory eff  ect on the angiogenesis induced by PT67/Nur77 cells 
(Fig. 9, A and B). [ID]FIG9[/ID] Thus, the angiogenesis induced by Nur77 
was not mediated through VEGFR-2/KDR and therefore 
not through VEGF-A.
Importance of Nur77’s transcriptional activity for in-
ducing angiogenesis. TR3/Nur77 is known to be a tran-
scription factor, but at least some of its activities, such as those 
involving neuron diff  erentiation and T cell apoptosis, occur in-
dependently of its transcriptional activity (11). To elucidate the 
mechanisms by which Nur77 mediates angiogenesis, we tested 
our Nur77 deletion mutants (Fig. 2 A) in Matrigel assays in 
vivo. Angiogenesis did not develop in Matrigels that included 
only PT67 cells packaging Nur77-∆TAD or Nur77-∆DBD 
(Fig. 10). [ID]FIG10[/ID] However, PT67 cells packaging Nur77-∆LBD in-
duced angiogenesis similar to that induced by SKMEL/VEGF 
cells or by full-length Nur77. Furthermore, inclusion of PT67 
cells packaging Nur77-∆TAD or Nur77-∆DBD PT67 mark-
edly inhibited the angiogenic response induced by SKMEL/
VEGF cells, whereas Nur77-∆LBD PT67 packaging cells had 
no inhibitory eff  ect. These data indicate that both the transacti-
vation and DNA binding domains are required for Nur77-
  mediated angiogenesis but that the LBD is not necessary.
DISCUSSION
TR3 and its mouse (Nur77) and rat (NGFI-B) homologues 
play important roles in tumor, lymphocyte, and neural 
Figure 8.  Growth of B16F1 melanoma is inhibited in Nur77−/− 
mice. (A) Growth of B16F1 melanomas in wild-type and Nur77−/− mice 
(mean + SD, n = 4). (B, a) Gross appearance of tumors at 11 d. Histology 
(b and c) and CD31 immunohistochemistry (d and e) of B16F1 melanomas 
growing in wild-type (b and d) and Nur77−/− (c and e) mice at day 11. 
Tumors in wild-type mice have numerous, large mother vessels (v), 
whereas vessels in Nur77−/− mice are much less numerous and consider-
ably smaller in size. N, necrosis; bar, 100 μm.
Figure 9.  Nur77 functions downstream of VEGFR-2/KDR in Matri-
gel assays in vivo. (A) SU1498, a VEGFR-2/KDR kinase inhibitor, inhibited 
angiogenesis induced by VEGF-A165–expressing SKMEL/VEGF-A cells (lane 1) 
but not that induced by Nur77 (lane 2). (B) Quantitative measurement 
of intravascular plasma volumes (μl/g) in Matrigels containing indicated 
cell mixtures ± SU1498 as determined by accumulation of Evan’s blue 
dye administered i.v. 5 min before killing.
Figure 10.  The transactivation and DNA binding domains of Nur77 
are required to induce angiogenesis in Matrigel assays in vivo. 
Quantitative measurement of intravascular plasma volumes (μl/g) in 3 d 
Matrigels containing indicated cell mixtures as determined by accumula-
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growth and survival (8, 20–22). TR3/Nur77/NGFI-B is 
diff  erentially expressed in brain and in many other tissues 
during development and is constitutively expressed at low 
levels in several adult tissues (23–27). It is highly induced as 
an immediate-early response gene in the adult nervous sys-
tem by growth factors, membrane depolarization, seizures, 
and by a variety of drugs and other stimuli (27–33). TR3 
and/or its mouse or rat homologues are also induced in anti-
gen-induced glomerulonephritis, in the regenerating liver, 
and by diverse stimuli in a variety of cultured cells (34, 35). 
Recently it has been implicated in the pathogenesis of hepa-
tocellular carcinoma induced by hepatitis B virus X protein 
(36) and was found to be one of nine genes whose down-
regulation in solid tumors correlated with reduced metastasis 
(37). In addition to regulating cell growth and diff  erentia-
tion, TR3/Nur77/NGFI-B has also been implicated in 
apoptosis in several types of cells, including T lymphocytes, 
the adult retina, and vascular smooth muscle cells, and sev-
eral carcinoma cell lines (8, 20–22). TR3 has also been de-
scribed as a death receptor in Alzeimer’s disease where it is 
expressed at high levels in neurons undergoing degeneration 
(38–41). Despite these important functions, Nur77 null mice 
lack a developmental phenotype, perhaps refl  ecting com-
pensation by closely related family members such as NOR1 
and NOT (10).
The data presented here extend the role of TR3-Nur77 
to a new fi  eld, that of VEGF-A–induced pathological an-
giogenesis. Two isoforms of VEGF-A, but not several other 
growth factors, induced TR3 expression in cultured vascular 
endothelial cells (Fig. 1). HUVECs in which TR3 was over-
expressed incorporated increased amounts of [3H]thymidine, 
were protected from apoptosis, and induced several cell cycle 
genes, all responses that are induced by VEGF-A in control 
HUVECs (Figs. 3 and 4). On the other hand, overexpres-
sion of antisense TR3 prevented HUVECs from respond-
ing to VEGF-A in these same assays and greatly diminished 
HUVEC tube formation on Matrigel. These in vitro fi  nd-
ings were extended in vivo to demonstrate that Nur77 was 
up-regulated in several examples of VEGF-A–mediated 
angiogenesis, including those induced by Ad-VEGF-A164, 
wound healing, and the growth of two VEGF-A–  expressing 
tumors, MOT and TA3/St (Fig. 5). In addition, making use 
of a recently modifi  ed Matrigel assay for expressing genes 
in endothelial cells in vivo, we demonstrated that introduc-
tion of Nur77-S DNA induced a typical angiogenic re-
sponse that was qualitatively and quantitatively equivalent 
to that induced by VEGF-A–expressing cells (Fig. 7). On 
the other hand, overexpression of Nur77-AS abrogated the 
angiogenic response expected from VEGF-A in this assay. 
The possibility that Nur77 was acting through VEGF-A was 
excluded by experiments demonstrating that a VEGF-A re-
ceptor inhibitor, SU1498, blocked the angiogenic response 
induced by VEGF-A but not that induced by Nur77 (Fig. 9). 
These fi  ndings, along with the fi  nding that the angiogenic 
response induced by Nur77 developed earlier than that in-
duced by VEGF-A, indicate that Nur77 acts independently 
and   downstream of VEGF-A. Finally, tumor growth and 
associated angiogenesis and mother vessel formation were 
signifi  cantly reduced in Nur77 null mice (Fig. 8). Collec-
tively, these data indicate that TR3-Nur77 is necessary and 
suffi   cient for VEGF-A–induced angiogenesis, both in vitro 
and in vivo.
TR3/Nur77/NGFI-B is an orphan member of the 
  steroid/thyroid/retinoid superfamily, whose members act 
mainly as transcription factors that induce or repress gene ex-
pression (10). However, several groups (11, 42, 43) have re-
cently shown that TR3’s ability to induce apoptosis in tumor 
cells is independent of transcription and occurs when TR3 
transmigrates from the nucleus to the cytoplasm. Like other 
members of its superfamily, TR3/Nur77 has three major do-
mains that regulate diff  erent functions (Fig. 2). These include 
NH2-terminal transactivation and DNA binding domains 
that are essential for regulating gene transcription, as well as a 
COOH-terminal LBD. Following the lead of Lin et al. (11), 
we prepared mutant forms of TR3/Nur77 that deleted each 
of these domains and transfected each of them into HUVECs. 
The diff  erent mutant forms exerted diff  erent eff  ects on 
HUVECs in diff  erent in vitro assays (Figs. 3 and 4). HUVECs 
transduced to express Nur77 mutants lacking the TAD or 
DBD domains incorporated [3H]thymidine at normal base-
line levels but could not be stimulated to increased incorpo-
ration by VEGF-A165. However, TR3-∆LBD mutants 
incorporated [3H]thymidine in similar amounts as full-length 
TR3, both without and with added VEGF-A165.
Overexpression of TR3-S was able to rescue HUVECs 
from apoptosis as eff  ectively as VEGF-A165. However, TR3 
mutants lacking any of the three domains were not able to do 
so (Fig. 3 B). These data therefore diff  er from those of Lin 
et al. (11) who found that the TAD and DBD domains were
not required for inducing apoptosis in tumor cells. TR3-
∆LBD HUVECs developed fairly good tube formation on 
Matrigel, whereas TR3-∆TAD–transfected HUVECs 
showed reduced tube formation and TR3-∆DBD–  transfected 
HUVECs were unable to form tubes; i.e., exhibited a stron-
ger inhibitory response than that of HUVECs transfected 
with Nur77-AS (Fig. 3 C). Finally, mutant HUVECs lacking 
the TAD or DBD domains expressed undetectable amounts 
of cell cycle genes under baseline conditions, and these genes 
were only minimally induced by the addition of VEGF-A165 
(Fig. 4). However, ∆LBD mutants behaved much like 
LacZ transfectants, expressing low levels of cell cycle genes 
under baseline conditions and greatly increased amounts 
upon stimulation with VEGF-A165. These data indicate that 
the transactivation and DNA binding domains of TR3 are 
required for TR3-mediated HUVEC proliferation, expres-
sion of cell cycle genes, and tube formation, functions that 
are therefore likely attributable to TR3’s transcriptional 
  activity. This fi  nding is not unexpected in the case of the 
∆DBD mutant that was localized to HUVEC cytoplasm and 
therefore not in position to perform transcriptional activity 
(Fig. 2 D). In agreement with these in vitro data, the intro-
duction of PT67 cells packaging Nur77 mutants lacking the JEM VOL. 203, March 20, 2006  727
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TAD or DBD domains was unable to induce an angiogenic 
response in the Matrigel assay, either alone or together with 
SKMEL/VEGF cells. However, PTK67 cells packaging 
Nur77-∆LBD, like those packaging Nur77-S, did induce an-
giogenesis in this assay, even in the absence of SKMEL/
VEGF cells. These data indicate that the transactivation do-
main and the DNA binding domain, but not the LBD, are 
needed for angiogenesis in vivo and are in agreement with a 
recent report indicating that the DNA binding and transacti-
vation domains of TR3/Nur77 are required for induction of 
cell proliferation in lung cancer cells (42).
Collectively, we have shown that TR3/Nur77 has an es-
sential downstream role in VEGF-A signaling in endothelial 
cells and have begun to dissect the roles of its several domains 
in regulating diff  erent endothelial cell functions. As far as we 
know, TR3/Nur77 is the fi  rst transcription factor found to 
regulate VEGF-A–mediated angiogenesis. As such, it could 
provide a useful target for positive and/or negative regulation 
of pathological angiogenesis.
MATERIALS AND METHODS
Cell culture. HUVEC culture and proliferation assays were performed 
as described previously (12). In brief, after 24 h of serum starvation, culture 
was continued with or without the addition of 10 ng/ml VEGF-A165 for an 
additional 20 h, followed by a fi  nal 4 h of culture with the addition of 
[3H]thymidine.
Construction of TR3/Nur77 mutants. TR3 and Nur77 cDNAs were 
obtained by RT-PCR with RNA isolated from HUVEC and mouse mes-
entery RNA, respectively. Mutants were generated by PCR-based muta-
genesis. After sequence confi  rmation, DNAs were fused with Flag tag or 
GFP to create Flag or GFP fusion proteins, respectively.
Endothelial cell tube formation assay. 105 HUVECs transduced with 
LacZ, TR3-S, TR3-AS, TR3-∆TAD, TR3-∆DBD, and TR3-∆LBD cDNAs 
were seeded on Matrigel with endothelial cell growth medium (Clonetics Co.) 
and photographed after 16 h. Experiments were repeated three times.
Cell survival assay. HUVECs transduced with LacZ, TR3-S, TR3-AS, 
TR3-∆TAD, TR3-∆DBD, or TR3-∆LBD were seeded on 100-mm tissue 
culture dishes. After 2 d, cells were changed to 0.1% BSA in EBM medium, 
with or without 50 ng/ml VEGF-A165, for 3 d. Cells were trypsinized, 
washed with PBS, and stained with propidium iodide solution (50 μg/ml 
propidium iodide in 0.1% sodium citrate–0.1% Triton X-100) for 1 h. 
Apoptotic cells were quantifi  ed by fl  ow cytometry. Experiments were re-
peated four times.
Quantitative real-time RT-PCR. Applied Biosystems software was used 
to design optimal primer pairs for real-time RT-PCR and data calcula-
tion. The forward and reverse primers for TR3 were 5′-A  G  C  A  T  T  A  T  G-
G  T  G  T  C  C  G  C  A  C  A  T  -3′ and 5′-C  T  T  G  G  C  G  T  T  T  T  T  C  T  G  C  A  C  T  G  T  -3′, 
respectively. 5′-/5TET/T  G  A  G  G  G  C  T  G  C  A  A  G  G  G  C  T  T  C  T  T  C  A  A  /36-
TAMNph/-3′ served as an internal probe for TR3. The primers for 
Nur77 were 5′-A  T  G  C  C  T  C  C  C  C  T  A  C  C  A  A  T  C  T  T  C  -3′ and 5′-C  A  G  T  G-
C  T  A  G  G  C  C   CGGAGTC-3′, respectively. The Nur77 internal probe was 
5′/5TET/C  A  C  T  T  C  C  C  T  C  A  T  C  C  G  G  G  C  A  C  A   CTT/36-TAMNph/-3′. 
GAPDH served as an internal control. Experiments were repeated three 
times, in duplicate.
In vivo angiogenesis models. 4–5-wk-old female Nu/Nu mice (National 
Institutes of Health [NIH]) were injected in ear skin with 108 PFU of non-
replicating adenoviral vectors expressing mouse VEGF-A164 (Ad-VEGF-A164) 
or LacZ (Ad-LacZ;  <CIT>reference 15 </CIT>). Other nude mice received 4-mm punch 
biopsies on their fl  anks or were injected i.p. with 106 MOT or TA3/St 
  mammary tumor cells (17, 44, 45). Ears and mesenteries were collected at in-
dicated times, and RNA and protein were isolated with the QIAGEN kit or 
the T-PER tissue protein extraction reagent (Pierce Biotechnology, Inc.), 
respectively. Experiments were repeated in triplicate.
In situ hybridization and immunohistochemistry. Tissues were har-
vested, photographed, and fi  xed in 4% paraformaldehyde. In situ hybridiza-
tion was performed as described previously (15) using Nur77-S and 
Nur77-AS probes representing the NH2-terminal 344 nucleotides. Immuno-
histochemistry was performed on frozen sections as described previously us-
ing rat anti-CD31 antibody (15).
Matrigel angiogenesis assays (18 </CIT>). 107 SK-MEL/VEGF cells, alone or 
mixed with 107 PT67 packaging cells infected with retroviruses expressing 
LacZ, Nur77-S or Nur77-AS cDNAs or Nur77 mutants, were suspended in 
0.5 ml of growth factor–reduced Matrigel (BD Biosciences) and injected s.c. 
into Nu/Nu mice. In some experiments, the KDR inhibitor SU1498 (Cal-
biochem) was incorporated into Matrigel plugs (40 μg/ml Matrigel) and also 
injected i.p. daily (1 mg/kg) after Matrigel implantation. Each experiment 
was replicated on eight mice.
Quantitative analysis of plasma volumes in Matrigel assays. Mice 
(four per group) implanted with various cell combinations in Matrigel were 
anesthetized with Avertin (200 mg/kg tribromoethanol) and injected i.v. via 
the tail vein with 0.2 ml of Evan’s blue dye (5 mg/ml in saline). After 5 min, 
blood was collected in heparin by cardiac puncture and centrifuged at 14,000 
rpm for 10 min to obtain platelet-poor plasma, which was diluted in for-
mamide for measurement of Evan’s blue dye concentration. Animals were 
killed by CO2 narcosis and Matrigel plugs were dissected free by cautery to 
prevent blood loss, weighed, and extracted with 2 ml formamide at room 
temperature for 3 d. Dye in plasma or extracted from Matrigels was mea-
sured at 620 nM in a Thermo Max microplate reader (Molecular Devices) 
using Softmax 881 software. Standard curves were generated by measure-
ment of serial dilutions of Evan’s blue dye in formamide (μg/ml). Intravas-
cular plasma volumes (μl per gram Matrigel) were calculated on the basis of 
Evan’s blue dye concentrations in blood plasma to provide an absolute mea-
sure of the volume of plasma in the vascular bed.
Tumor growth in wild-type and Nur77−/− mice. Nur77−/− mice 
were provided by J. Milbrandt (Washington University School of Medicine, 
St. Louis, MO). 5 × 105 B16F1 melanoma cells (American Type Culture 
Collection) were injected into the fl  ank skin of wild-type (C57BL/6) and 
Nur77−/− mice. Tumor size was measured daily and animals were killed 
on day 11 when tumors in control animals had reached a size of nearly 
1,500 mm3. Tumor size was calculated as the product of π/6 times the mea-
sures of the tumor’s length, width, and height. Tissues were prepared for 
1 μm   Giemsa-stained Epon sections and for immunohistochemistry as 
described previously (15).
Statistics. Analysis of variance and the Tukey-Kramer multiple compari-
sons test were used to determine statistical signifi  cance.
Animal welfare. All animal experiments were performed in compliance 
with the Beth Israel Deaconess Medical Center Institutional Animal Care 
and Use Committee.
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